‘Concerning’ increases in anal cancer, FDA OKs Oxbryta for sickle cell disease — top stories in hematology/oncology
Researchers recently reported a “concerning” increase in the incidence of anal cancer and related mortality, and the FDA approved a once-daily oral agent for sickle cell disease called Oxbryta.
Access these and more top stories in hematology/oncology here.
Anal cancer incidence, mortality rise sharply in US
Rates of squamous cell carcinoma of the anus and related mortality have risen sharply over the past 15 years, according to results of a retrospective study published in Journal of the National Cancer Institute. Read more.
FDA approves Oxbryta for sickle cell disease
The FDA granted accelerated approval to voxelotor for the treatment of sickle cell disease. Read more.
FDA grants priority review to pemigatinib for cholangiocarcinoma
The FDA granted priority review to pemigatinib for the treatment of patients with previously treated, locally advanced or metastatic cholangiocarcinoma and FGFR2 fusions or rearrangements, according to a press release from the agent’s manufacturer. Read more.
Polatuzumab vedotin regimen induces complete responses in relapsed/refractory diffuse large B-cell lymphoma
Polatuzumab vedotin combined with bendamustine and rituximab demonstrated encouraging rates of complete response among patients with transplantation-ineligible, relapsed/refractory diffuse large B-cell lymphoma, according to results of a phase 1b/phase 2 trial published in Journal of Clinical Oncology. Read more.
Lower recurrence score threshold associated with mortality risk among men with breast cancer
Oncotype DX Breast Recurrence Score appeared to be associated with mortality at a lower threshold for men with breast cancer than for their female counterparts, according to results of a retrospective study published in Clinical Cancer Research. Read more.